Rahul Bhargava, Director and Head of Hematology, Hemat0-oncology, and Stem Cell Transplant at Fortis Health Care, shared a post on LinkedIn:
“Dr. Neha Rastogi Panda Making us proud by working hard to collect this data and publish first from India
Proving –
1) No statistically significant differences were observed between innovator and bioequivalent
letermovir formulations with respect to safety or CMV outcomes. Availability of a cost-effective bioequivalent formulation may substantially expand access to CMV prophylaxis, supporting improved
transplant outcomes in high-burden LMICs.
2) one less thing to worry about during BMT
We are really proud of her.”
Title: Letermovir Prophylaxis for Cytomegalovirus Infection in Adult Allogeneic Stem Cell Transplantation: A Retrospective Analysis From a Lower-Middle-Income Country
Authors: Neha Rastogi, Swati Bhayana, Kapil Chahal, Nikhil M. Kumar, Anusha Swaminathan, Ashutosh Panda, Suyash Bharat, Onyeaghala Chizaram, Shrinidhi Nathany, Anindita Paul, Rachit Agrawal, Vikas Dua, Rahul Bhargava
Read The Full Article
More posts featuring Rahul Bhargava on OncoDaily.
